CROI 2022

Conference on Retroviruses and Opportunistic Infections (CROI) 2022

CROI facilitates the presentation of important research discoveries in HIV, hepatitis viruses, SARS-CoV-2, and other viral infections and their related conditions. CROI 2022 is a fully virtual conference, starting February 12 - 16 with additional symposia on February 22, 23, and 24.

CROI 2022 Program Guide

CROI 2022 Conference Website

Listed below are CROI 2022 oral abstract sessions (OA) and poster sessions (PS) affiliated with the HIV/AIDS Clinical Trials Networks. All sessions are listed in North American Mountain Time (MT).

Monday, February 14, 2022

9:45 AM - 11:45 AM MT: Oral Abstract Sessions

Time (MT)	Abstract Title	Presenting Author	Protocol
10:14 AM	Growth Of Infants with Perinatal Exposure to Maternal DTG vs EFV and TDF vs TAF	Lynda Stranix-Chibanda	IMPAACT 2010
10:45 AM	Two Year Virologic Outcomes of Very Early ART for Infants in the IMPAACT P1115 Study	Deborah Persaud	IMPAACT P1115

Time (MT)	Abstract Title	Presenting Author	Protocol
9:50 AM	Geographical Differences in Functional Impairment of People with HIV	Kristine Erlandson	ACTG 5332/ REPRIEVE

Time (MT)	Abstract Title	Presenting Author	Protocol
10:14 AM	SARS-CoV-2 Prevalence in Children and Adults in 15 US Communities: The COMPASS Study	Jessica E. Justman	CoVPN 5002
11:09 AM	COVID-19 Vaccination Rates in a Global HIV Cohort	Evelynne S. Fulda	ACTG 5332/ REPRIEVE

2:00 PM - 3:30 PM MT: Live Chat Sessions with Poster Presenters

Abstract Title	Presenting Author	Protocol
N-Glycosylation Site Signatures of HIV Envelope in Post-Treatment Controllers	Elmira Esmaeilzadeh	NWCS 380

Abstract Title	Presenting Author	Protocol
Post-Treatment Controllers Limit Completed and Spliced HIV Transcripts After ATI	Adam Wedrychowski	NWCS 380
Post-Treatment Controllers Maintain a Limited Intact Reservoir After ART Interruption	Yijia Li	ACTG 5068

Abstract Title	Presenting Author	Protocol
H/L-Ferritins and Tim-1 Associate with Neurocognitive Function in People with HIV	Asha R. Kallianpur	ACTG 5322/ HAILO
Associations Between Plasma Biomarkers and Neurocognition in ART-Treated PWH	Robert Kalayjian	NWCS 447

Abstract Title	Presenting Author	Protocol
HIV Drug Resistance in Women Randomized to DTG vs EFV or TDF vs TAF in Pregnancy	Ceejay L. Boyce	IMPAACT 2010

Abstract Title	Presenting Author	Protocol
NAFLD is Common Among REPRIEVE Participants and Associated with Cardiovascular Risk	Carl J. Fichtenbaum	ACTG 5332/ REPRIEVE

Abstract Title	Presenting Author	Protocol
Subclinical Atherosclerosis and Immune Activation Among US Females vs. Males with HIV	Markella V. Zanni	ACTG 5332/ REPRIEVE

Abstract Title	Presenting Author	Protocol
L-Ferritin and Tim-1 are Associated with Frailty Measures in People with HIV	Asha R. Kallianpur	ACTG 5322/ HAILO

Abstract Title	Presenting Author	Protocol
Post-Acute Sequelae of SARS-CoV-2 in NonHospitalized ACTIV-2 Trial Participants	Teresa H. Evering	ACTG 5401/ ACTIV-2

Abstract Title	Presenting Author	Protocol
ACTG A5351S: Effect of Immune-Modulatory Interventions on CMV Replication During ART	Elizabeth Hastie	ACTG 5351s

Abstract Title	Presenting Author	Protocol
Pregnancy Hemoglobin A1c and glucose with DTG vs EFV, TDF vs TAF: IMPAACT 2010	Lameck Chinula	IMPAACT 2010
Weight Gain with Raltegravir vs. Efavirenz During Pregnancy	Conrado M. Coutinho	NICHD P1081

Abstract Title	Presenting Author	Protocol
Association of Maternal TDF-containing ART with Bone Mineral Content in Breastfed Infants	Tichaona Vhembo	PROMISE P1084s

Abstract Title	Presenting Author	Protocol
Estimating Benefits From Using On-Demand Oral PrEP by MSM in US: A Modeling Study	Sarah Stansfield	HPTN Modelling Centre

Tuesday, February 15, 2022

9:45 AM - 11:45 AM MT: Oral Abstract Sessions

Time (MT)	Abstract Title	Presenting Author	Protocol
10:14 AM	HIV-1 Remission with CCR5Δ32Δ32 Haplo-Cord Transplant in a US Woman: IMPAACT P1107	Yvonne Bryson	IMPAACT P1107

Time (MT)	Abstract Title	Presenting Author	Protocol
11:01 AM	PK of Dose-Adjusted Emergency Contraception with Rifampicin Therapy in ACTG A5375	Rosie Mngqibisa	ACTG 5375
11:09 AM	DTG PK in People with HIV Receiving Daily 1Hp for Latent Tb Treatment	Anthony T. Podany	ACTG 5372

Time (MT)	Abstract Title	Presenting Author	Protocol
9:58 AM	Phase I Study of Combination Anti-HIV Neutralizing Antibodies in HIV-Negative Adults	Magdalena E. Sobieszcyk	HVTN 130/ HPTN 089
11:01 AM	Counterfactual Estimation of CAB-LA Efficacy Against Placebo Using External Trial Data	Deborah Donnell	HPTN 084
11:09 AM	Different HIV Protection for Traditional and Medical Circumcision in HPTN 071 (POPART)	Kidist B. Zewdie	HPTN 071

Time (MT)	Abstract Title	Presenting Author	Protocol
11:01 AM	Updated Efficacy, Safety, and Case Studies in HPTN 083: CAB-LA vs. TDF/FTC for PrEP	Raphael J. Landovitz	HPTN 083
11:09 AM	CAB-LA PrEP: Early Detection of HIV Infection may Reduce INSTI Resistance Risk	Susan Eshleman	HPTN 083

Time (MT)	Abstract Title	Presenting Author	Protocol
9:50 AM	Symptom Duration in COVID-19 Convalescent Patients: Regional & Clinical Associations	Jorge A. Gallardo-Cartagena	HVTN 405/ HPTN 1901
11:17 AM	Camostat is not Effective for Mild-Moderate COVID-19 in a Phase II Trial of ACTIV-2	Nikolaus Jilg	ACTG 5401/ ACTIV-2

1:15 PM - 2:00 PM MT: Special SEssioN: Anal Cancer Prevention and Management

Treatment of Anal High-grade Squamous Intraepithelial Lesions to Prevent Anal Cancer
Presenting Author: Joel Palefsky
Protocol: ANCHOR study

2:00 PM - 3:30 PM MT: Live Chat Sessions with Poster Presenters

Abstract Title	Presenting Author	Protocol
T Cells Expressing Multiple Inhibitory Receptors Persist on Long-Term ART	Bernard J. Macatangay	ACTG 5321
Inhibitory Receptor Expression Correlates with HIV Persistence and Immune Responses	Bernard J. Macatangay	ACTG 5321
HIV-Specific T Cell Frequencies and Function After ART During Acute or Early HIV	Scott F. Sieg	ACTG 5354

Abstract Title	Presenting Author	Protocol
Size and Activity of the HIV Reservoir Predict Rebound Timing After ART Interruption	Jonathan Li	ACTG 5345
Early Antiretroviral Therapy Reduces But Does Not Eliminate HIV DNA in Blood	Trevor A. Crowell	ACTG 5354

Abstract Title	Presenting Author	Protocol
Phase-2 Evaluation of Sab-185, a Polyclonal Antibody Treatment for COVID-19 in ACTIV-2	Babafemi O. Taiwo	ACTG 5401/ ACTIV-2

Abstract Title	Presenting Author	Protocol
Adherence in The ACTG 5360 HCV Minimal Monitoring (MINMON) Trial	Leonard Sowah	ACTG 5360/ MINMON

Abstract Title	Presenting Author	Protocol
Proteinuria is Common Among People with HIV with Controlled HIV Viremia	Edgar T. Overton	ACTG 5332/ REPRIEVE

Abstract Title	Presenting Author	Protocol
IMPAACT 2032: Remdesivir PK & Safety in Pregnant and Non-pregnant Women with COVID-19	Kristina M. Brooks	IMPAACT 2032

Abstract Title	Presenting Author	Protocol
Risk-benefit Trade-off for Pregnancy and Infant Outcomes: DTG, EFV, TAF, and TDF	Sean Brummel	IMPAACT 2010
Adverse Outcomes in Subsequent Pregnancies in the IMPAACT 2010 Trial	Lee Fairlie	IMPAACT 2010
Impact of Maternal Hepatitis B Virus Co- infection on Pregnancy and Infant Outcomes in the Promoting Maternal and Infant Survival Everywhere (PROMISE) Study	Flavia K. Matovu	PROMISE 1077BF/1077FF

Abstract Title	Presenting Author	Protocol
Is Routine PCP Prophylaxis Needed in Very Early-treated Infants with HIV?	Bryan S. Nelson	IMPAACT P1115

Abstract Title	Presenting Author	Protocol
Asymptomatic SARS-CoV-2 Infection is Extremely Common Among People with HIV	Edgar T. Overton	ACTG 5332/ REPRIEVE

Abstract Title	Presenting Author	Protocol
A Tool to Assess HIV Prevention Readiness of Adolescent Girls and Young Women	Geetha Beauchamp	HPTN 082

Wednesday, February 16, 2022

9:45 AM - 11:45 AM MT: Oral Abstract Sessions

Time (MT)	Abstract Title	Presenting Author	Protocol
11:09 AM	ACTG A5324: A randomized trial of ART intensification for cognitive impairment in PWH	Scott Letendre	ACTG 5324

2:00 PM - 3:30 PM MT: Live Chat Sessions with Poster Presenters

Abstract Title	Presenting Author	Protocol
Immune Responses Following Anti-PD-1 Monoclonal Antibody Infusion in Persons with HIV	Bernard J. Macatangay	ACTG 5370
Ex Vivo Assay Predicts HIV-1 Suppression by bNAbs Infused in a Phase I Clinical Trial	Sabrina Helmold Hait	ACTG 5378

Abstract Title	Presenting Author	Protocol
HIV Envelope Diversity and Sensitivity to bNAbs Across Stages of Acute and Early HIV	Laurie VanderVeen	ACTG 5354

Abstract Title	Presenting Author	Protocol
Impact of Integrase Strand Transfer Inhibitors on Cognition in the HAILO Cohort	Jane O'Halloran	ACTG 5322/ HAILO

Abstract Title	Presenting Author	Protocol
Efficacy of Tenofovir-Lamivudine-Dolutegravir for Initial and First-Line Switch ART	Cissy Kityo	ACTG 5381

Abstract Title	Presenting Author	Protocol
Feasibility and Viral Response to Treating Acute/Early HIV in a Multinational Study	Eric S. Daar	ACTG 5354

Abstract Title	Presenting Author	Protocol
Pharmacogenetics of Weight Gain After Switch to Integrase Inhibitor-Based Regimens	David W. Haas	DACS 349

Abstract Title	Presenting Author	Protocol
Evaluation of CAB-LA Safety and PK in Pregnant Women in the Blinded Phase of HPTN 084	Sinead Delany-Moretlwe	HPTN 084

Abstract Title	Presenting Author	Protocol
Extended Safety and PK and Anti-HIV Monoclonal AB VRC07-523LS in HIV-exposed Infants	Coleen K. Cunningham	IMPAACT P1112
IMPAACT 2019: PK & Safety of Dispersible ABC/DTG/3TC in Children with HIV 6 to <14 kg	Kristina M. Brooks	IMPAACT 2019
Safety and PK of Long-acting Cabotegravir and Rilpivirine in Adolescents	Aditya H. Gaur	IMPAACT 2017
Adolescent and Parent Experiences with Long- acting Injectables in the MOCHA Study	Elizabeth D. Lowenthal	IMPAACT 2017

Abstract Title	Presenting Author	Protocol
Expectations of Preventive Benefits and HIV-Related Risk Behaviors in HPTN 069/ACTG 5305	Jeremy Sugarman	HPTN 069/ ACTG 5305

Conference on Retroviruses and Opportunistic Infections (CROI) 2022

Monday, February 14, 2022

OA2: Maternal and Child Health: New Insights into Hepatitis, SARS-CoV-2

OA3: Malignancies and Comorbidities: An Increasing Burden

OA4: Evolving Epidemiology of HIV and SARS-CoV-2

PS-A01: Infection and Envelope

PS-E04: Controllers and Post-Treatment Controllers

PS-F04: Blood and CSF Biomarkers of Brain Integrity and Function

PS-I02: Impact of HIV Mutations on Fitness, Drug Resistance, and Treatment Response Session

PS-J01: Fatty Liver: NAFL, MAFL, and NASH

PS-L01: Risk Factor and Inflammatory Mediators of Cardiovascular Disease

PS-M04: Frailty and Sleep Disturbances

PS-N01: Post-acute Sequelae of SARS-CoV-2 Infection

PS-O05: CMV and Fungal Opportunistic Infections

PS-P03: Evolving Insights: MTCT Risk to Maternal Health Session

PS-P04: New Perspectives on the Health of Children Exposed to HIV In Utero Session

PS-V01: PrEP: Services, Cost-Effectiveness, Bone Loss, and ARV Resistance

Tuesday, February 15, 2022

OA5: HIV Reservoirs and Cure Strategies Session

OA6: Tuberculosis, Opportunistic Infections, and Hepatitis

OA7: HIV Prevention: From the Bend to Population

OA8: Global Perspectives on HIV Testing, Treatment, and Prevention

OA9: SARS-CoV-2 Antivirals and Outcomes

PS-D03: HIV Immunology: T Cells

PS-E06: Dynamics of HIV Reservoirs and Viral Rebound

PS-H01: Clinical Trials of Therapy for SARS-CoV-2: Antivirals and Immune Modifiers

PS-J02: HCV Treatment and Disease

PS-M03: Other Comorbidities

PS-P01: COVID-19 in Mothers and Their Children Session

PS-P02: HIV, ART, and Pregnancy Outcomes: Epidemiology and Mechanisms Session

PS-Q02: Early Treatment and HIV Reservoirs in Children Session

PS-R01: SARS-CoV-2 Epidemiology

PS-V02: PrEP in Adolescents and Pregnant People

Wednesday, February 16, 2022

OA11: Crossing the CNS Border: HIV, SIV, and SARS-CoV-2

PS-D05: HIV Immune Therapy

PS-E05: Immune Pressures on the HIV Reservoir

PS-F02: ART: Efficacy, Switches, and Toxicity

PS-H03: Antiretroviral Therapy in Experienced Patients: Sustain or Regain Suppression

PS-H04: First-line Therapy, Low-level Viremia, and Adherence

PS-M01: Weight Gain and Adipose Tissue Biology

PS-P05: HIV Infection and Prevention in Pregnancy

PS-Q05: PK, Safety, and Acceptability of New Agents for Children and Youth Session

PS-V04: Early Phase Studies of HIV Vaccines, bNAbs, and Next-Generation PrEP